Discontinuation of alendronate and administration of bone-forming agents after surgical nailing may promote union of atypical femoral fractures in patients on long-term alendronate therapy

被引：8

作者：

Lin T.-L. ^{[1
]}

Wang S.-J. ^{[1
]}

Fong Y.-C. ^{[1
]}

Hsu C.-J. ^{[1
]}

Hsu H.-C. ^{[1
]}

Tsai C.-H. ^{[1
]}

机构：

[1] Department of Orthopaedic Surgery, China Medical University, China Medical University Hospital, Taichung

来源：

BMC Research Notes | / 6卷 / 1期

关键词：

Alendronate; Atypical femoral fracture; Bone-forming agents; Union;

D O I：

10.1186/1756-0500-6-11

中图分类号：

学科分类号：

摘要：

Background: Long-term alendronate therapy may lead to atypical femoral fractures in a very few patients. However, the management protocol to optimize fracture healing remains undetermined. The purpose of this study was to describe the time to union of atypical femoral fractures after surgical nailing in patients on long-term alendronate therapy, with continuation of alendronate or discontinuation of alendronate, and administration of bone-forming agents. Findings. From January 2004 to December 2011, the records of patients at our institution on long-term alendronate therapy for more than 36 months and sustaining atypical femoral fractures that had undergone surgical nailing, with continuation of alendronate or discontinuation of alendronate and administration of bone-forming agents were reviewed.During the 8-year study period, we treated 10 atypical femoral fractures with surgical nailing in 7 consecutive osteopenic or osteoporotic patients on long-term alendronate therapy for more than 36 months. There were no post-operative complications or needs for revision surgery. All fractures achieved union during follow-up. Mean union time was 23.5 months (range, 18-31 months) for 6 fractures with continuation of alendronate after surgery, and 4.5 months (range, 4-5 months) for 4 fractures with discontinuation of alendronate and administration of bone-forming agents after surgery. Conclusions: Discontinuation of alendronate and administration of bone-forming agents after surgical nailing may promote union of atypical femoral fractures in patients on long-term alendronate therapy. © 2013 Lin et al.; licensee BioMed Central Ltd.

引用

共 21 条

[1]

Odvina C.V., Zerwekh J.E., Rao D.S., Maalouf N., Gottschalk F.A., Pak C.Y.C., Severely suppressed bone turnover: A potential complication of alendronate therapy, Journal of Clinical Endocrinology and Metabolism, 90, 3, pp. 1294-1301, (2005)

[2]

Visekruna M., Wilson D., McKiernan F.E., Severely suppressed bone turnover and atypical skeletal fragility, J Clin Endocrinol Metab, 93, 8, pp. 2948-2952, (2008)

[3]

Carvalho N.N., Voss L.A., Almeida M.O., Salgado C.L., Bandeira F., Atypical femoral fractures during prolonged use of bisphosphonates: Short-term responses to strontium ranelate and teriparatide, J Clin Endocrinol Metab, 96, 9, pp. 2675-2680, (2011)

[4]

Dobnig H., Stepan J.J., Burr D.B., Li J., Michalska D., Sipos A., Petto H., Fahrleitner-Pammer A., Pavo I., Teriparatide reduces bone microdamage accumulation in postmenopausal women previously treated with alendronate, J Bone Miner Res, 24, 12, pp. 1998-2006, (2009)

[5]

Jobke B., Pfeifer M., Minne H.W., Teriparatide following bisphosphonates: Initial and long-term effects on microarchitecture and bone remodeling at the human iliac crest, Connect Tissue Res, 50, 1, pp. 46-54, (2009)

[6]

Rizzoli R., Laroche M., Krieg M.A., Frieling I., Thomas T., Delmas P., Felsenberg D., Strontium ranelate and alendronate have differing effects on distal tibia bone microstructure in women with osteoporosis, Rheumatol Int, 30, 10, pp. 1341-1348, (2010)

[7]

Chiang C.Y., Zebaze R.M., Ghasem-Zadeh A., Iuliano-Burns S., Hardidge A., Seeman E., Teriparatide improves bone quality and healing of atypical femoral fractures associated with bisphosphonate therapy, Bone, 52, 1, pp. 360-365, (2012)

[8]

Shane E., Burr D., Ebeling P.R., Abrahamsen B., Adler R.A., Brown T.D., Cheung A.M., Cosman F., Curtis J.R., Dell R., Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral research, J Bone Miner Res, 25, 11, pp. 2267-2294, (2010)

[9]

Weil Y.A., Rivkin G., Safran O., Liebergall M., Foldes A.J., The outcome of surgically treated femur fractures associated with long-term bisphosphonate use, J Trauma, 71, 1, pp. 186-190, (2011)

[10]

Schilcher J., Michaelsson K., Aspenberg P., Bisphosphonate use and atypical fractures of the femoral shaft, N Eng J Med, 364, 18, pp. 1728-1737, (2011)

← 1 2 3 →